Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Pharmaceutical Manufacturing topic
No spam. Unsubscribe anytime.
Committee approves conditional state licenses for virtual drug manufacturers
Summary
The House Health Committee reported House Bill 21-62 as amended, creating a conditional state license for virtual manufacturers while their FDA applications are pending; the amendment requires applicants to list application numbers and contracts, converts conditional licenses to full licenses within 30 days of FDA approval and expires them after one year without approval.
The House Health Committee voted to report House Bill 21-62 as amended on a roll call, advancing legislation that would allow virtual manufacturers of FDA-regulated prescription drugs to obtain a conditional Pennsylvania license while their FDA application remains under review.
Rep. Borowski, the bill sponsor, said the measure aims to remove a barrier that prevents companies from making Pennsylvania their home state. “This actually is an exciting piece of legislation,” Borowski said, describing the change as a way for biotech firms to begin state licensing concurrently with FDA review and be able to pursue licensing in other states while waiting for federal approval.
An amendment adopted in committee (A03371) creates a conditional license that requires the applicant to list its FDA application number and any contracts for manufacturing or distribution, and to notify the Department of Health if the FDA approves, denies or withdraws the application. Under the amendment, a conditional license expires if FDA approval is not granted within one year; if the FDA grants approval, the conditional license must convert to a full state license within 30 days.
Chair Rapp said Pennsylvania is one of nine states that require FDA approval before state licensure, a rule that can delay companies establishing operations in the Commonwealth. She supported the amendment’s approach to allow conditional licensing while preserving safeguards to avoid issuing permanent licenses prior to federal approval.
Committee staff told members the change would remove an obstacle that has led some companies to headquarter elsewhere, while maintaining regulatory guardrails. The committee recorded a roll-call vote after discussion; the chair announced the bill will be reported to the next legislative stage as amended.
The committee also heard that industry stakeholders, including a company called Mineralis and other life-sciences organizations, helped staff craft the amendment. No appropriation or fiscal detail was included with the bill itself; the measure changes licensing conditions rather than directly authorizing new spending.
The committee’s action advances the bill for further consideration by the Legislature; the committee did not set a date for any subsequent floor action.
